Regulus Continues to Aim for Two INDs in 2014, Expects miRNA Biomarker Data in Q3 | GenomeWeb

Officials from Regulus Therapeutics this week said that the company continues to plan on filing two investigational new drug applications in 2014, one of which is for a microRNA-122-targeting hepatitis C treatment, but fell short of promising the goal would be met.

The comments, which were made during a conference call held to discuss Regulus' fourth-quarter financial results, contrast with those made by the executives in November, when they said they would nominate two clinical candidates before the end of 2013 and file two INDs the following year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.